News >

Update Confirms Benefit of Pembrolizumab Plus Indoximod in Melanoma

Jason M. Broderick @jasoncology
Published: Thursday, Sep 07, 2017

Charles J. Link, Jr, MD

Charles J. Link, Jr, MD
Adding the IDO inhibitor indoximod to pembrolizumab (Keytruda) led to an overall response rate (ORR) of 61% in patients with advanced melanoma, according to updated phase II data scheduled to be presented at the Third International Cancer Immunotherapy Conference in Frankfurt/Mainz, Germany.

“Our team is excited to move forward with this pivotal trial,” Eugene Kennedy, MD, vice president of Clinical and Medical Affairs at NewLink, said in a statement. “We believe that allowing physicians the choice of either pembrolizumab or nivolumab accurately reflects current clinical care and should aid in enrolling the trial by the end of 2018.”
1. Zachariah Y, McWilliams R, Shaheed M, et al. Interim analysis of the Phase 2 clinical trial of the IDO pathway inhibitor indexed in combination with pembrolizumab for patients with advanced melanoma. Presented at: 2017 AACR Annual Meeting; April 1-5, 2017; San Washington, DC. Abstract CT117.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Melanoma: Exploring BRAF/MEK in Adjuvant and Neoadjuvant SettingsSep 28, 20191.5
Medical Crossfire®: What Does Data Tell Us About How to Optimize Checkpoint Inhibitor Strategies Across Lines of Care for Patients with Melanoma?Nov 30, 20191.5
Publication Bottom Border
Border Publication